Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

NCT02775916 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG: CDZ173
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals